After review of the program's full development strategy, GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications and will stop further development work on the intravenous route of administration in autoimmune disease.
Based on the positive results from the Phase I/II study in multiple sclerosis (MS) that were announced on 10th September, GSK plans to begin a Phase IIB dose ranging study in MS using the subcutaneous administration of ofatumumab in 2011following discussion with regulatory authorities. Further work in rheumatoid arthritis (RA) with a subcutaneous administration of ofatumumab is under review.
"Although the intravenous delivery of ofatumumab has previously demonstrated positive results in MS and RA studies, the autoimmune program is being refocused on the subcutaneous delivery of ofatumumab because GSK believes this route of administration has the potential to offer added convenience and improved tolerability," said Ian Tomlinson, SVP Biopharmaceuticals R&D, GSK.
"Genmab initiated the early development of ofatumumab in the autoimmune indications and we are pleased and highly supportive of GSK's continued commitment to the development of ofatumumab in these chronic diseases," said JanG. J. van de Winkel, Ph.D., President and CEO, Genmab.
Ofatumumab is currently not licensed for any autoimmune indications. GSK and Genmab will continue their development of ofatumumab in multiple oncology indications with the intravenous route of administration.
Based on the positive results from the Phase I/II study in multiple sclerosis (MS) that were announced on 10th September, GSK plans to begin a Phase IIB dose ranging study in MS using the subcutaneous administration of ofatumumab in 2011following discussion with regulatory authorities. Further work in rheumatoid arthritis (RA) with a subcutaneous administration of ofatumumab is under review.
"Although the intravenous delivery of ofatumumab has previously demonstrated positive results in MS and RA studies, the autoimmune program is being refocused on the subcutaneous delivery of ofatumumab because GSK believes this route of administration has the potential to offer added convenience and improved tolerability," said Ian Tomlinson, SVP Biopharmaceuticals R&D, GSK.
"Genmab initiated the early development of ofatumumab in the autoimmune indications and we are pleased and highly supportive of GSK's continued commitment to the development of ofatumumab in these chronic diseases," said JanG. J. van de Winkel, Ph.D., President and CEO, Genmab.
Ofatumumab is currently not licensed for any autoimmune indications. GSK and Genmab will continue their development of ofatumumab in multiple oncology indications with the intravenous route of administration.
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)